Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240694 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT01240694 is a Phase 3 study that was terminated before completion, run by Cephalon. The registered enrollment target is 136 participants.
The verdict
NCT01240694, a Phase 3 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (SC) CEP-33457 for injection every 4 weeks over 72 weeks (18 doses) in participants with systemic lupus erythematosus (SLE) who have participated in a previous Cephalon sponsored clinical study of CEP-33457, and completed at least Visit 8 (Week 24 of that study).
Interventions
- DRUG CEP-33457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2010-12-09 |
| Est. Completion | 2012-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240694
The ClinicalTrials.gov registry entry for NCT01240694 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CEP-33457 is the first listed.
NCT01240694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240694 about?
NCT01240694 is a clinical study titled "A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus". The primary objective of this study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (SC) CEP-33457 for injection every 4 weeks over 72 weeks (18 doses) in participants with systemic lupus erythematosus (SLE) who have participated in a previous Cephalon...
What is the current status of trial NCT01240694?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2010-12-09. Estimated completion is 2012-06-14.
What interventions are being tested in trial NCT01240694?
The interventions under investigation include: CEP-33457 (DRUG).
Who is sponsoring clinical trial NCT01240694?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.